These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31689108)

  • 21. Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs.
    Dogné JM; Thiry A; Supuran CT
    Curr Pharm Des; 2008; 14(7):679-84. PubMed ID: 18336314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
    Migliore M; Habrant D; Sasso O; Albani C; Bertozzi SM; Armirotti A; Piomelli D; Scarpelli R
    Eur J Med Chem; 2016 Feb; 109():216-37. PubMed ID: 26774927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile.
    Abdelazeem AH; El-Saadi MT; Safi El-Din AG; Omar HA; El-Moghazy SM
    Bioorg Med Chem; 2017 Jan; 25(2):665-676. PubMed ID: 27916468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer.
    De Monte C; Carradori S; Gentili A; Mollica A; Trisciuoglio D; Supuran CT
    Curr Med Chem; 2015; 22(24):2812-8. PubMed ID: 26180003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.
    Biava M; Porretta GC; Poce G; Battilocchio C; Botta M; Manetti F; Rovini M; Cappelli A; Sautebin L; Rossi A; Pergola C; Ghelardini C; Galeotti N; Makovec F; Giordani A; Anzellotti P; Tacconelli S; Patrignani P; Anzini M
    Curr Med Chem; 2011; 18(10):1540-54. PubMed ID: 21428878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of cyclooxygenase-2-specific inhibitors.
    Cannon GW; Breedveld FC
    Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.
    Hedner T; Samulesson O; Währborg P; Wadenvik H; Ung KA; Ekbom A
    Drugs; 2004; 64(20):2315-43; discussion 2344-5. PubMed ID: 15456329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors.
    Kalgutkar AS; Marnett AB; Crews BC; Remmel RP; Marnett LJ
    J Med Chem; 2000 Jul; 43(15):2860-70. PubMed ID: 10956194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclooxygenase-2 specificity and its clinical implications.
    Lefkowith JB
    Am J Med; 1999 May; 106(5B):43S-50S. PubMed ID: 10390127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carbonic anhydrase inhibition by flurbiprofen and related agents.
    Greene IM; Arifullah M; Kenny AD
    Pharmacology; 1992; 45(5):278-84. PubMed ID: 1465474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, characterization, evaluation and molecular dynamics studies of 5, 6-diphenyl-1,2,4-triazin-3(2H)-one derivatives bearing 5-substituted 1,3,4-oxadiazole as potential anti-inflammatory and analgesic agents.
    Banerjee AG; Das N; Shengule SA; Srivastava RS; Shrivastava SK
    Eur J Med Chem; 2015 Aug; 101():81-95. PubMed ID: 26117820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
    Bertolini A; Ottani A; Sandrini M
    Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
    Lee MC; Lee S; Suh DC; Kim J; Kong SX;
    Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of potent anti-convulsant carbonic anhydrase inhibitors: Design, synthesis, in vitro and in vivo appraisal.
    Mishra CB; Kumari S; Angeli A; Bua S; Buonanno M; Monti SM; Tiwari M; Supuran CT
    Eur J Med Chem; 2018 Aug; 156():430-443. PubMed ID: 30015076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonsteroidal antiinflammatory drugs: benefits, risks, and COX-2 selectivity.
    Halverson PB
    Orthop Nurs; 1999; 18(6):21-6; quiz 27-8. PubMed ID: 11062611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New drugs for the treatment of rheumatoid arthritis.
    Schuna AA; Megeff C
    Am J Health Syst Pharm; 2000 Feb; 57(3):225-34. PubMed ID: 10674776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs in the management of arthritis.
    Kraus VB
    Foot Ankle Clin; 2003 Jun; 8(2):187-200, vii. PubMed ID: 12911235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs.
    Poddubnyy D; Song IH; Sieper J
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S148-51. PubMed ID: 19822063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.